Sabby Management, LLC Virpax Pharmaceuticals, Inc. Transaction History

Sabby Management, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$0.76 - $1.1 $81,479 - $117,931	-107,210 Reduced 26.8%	292,790 $234,000
Q2 2023 Aug 14, 2023	SELL	$0.64 - $1.09 $192,931 - $328,585	-301,455 Reduced 42.98%	400,000 $432,000
Q1 2023 May 15, 2023	SELL	$0.67 - $1.15 $192,095 - $329,716	-286,710 Reduced 29.01%	701,455 $547,000
Q4 2022 Feb 14, 2023	SELL	$0.62 - $12.0 $41,065 - $794,820	-66,235 Reduced 6.28%	988,165 $612,000
Q3 2022 Nov 14, 2022	SELL	$1.15 - $11.9 $5,730 - $59,297	-4,983 Reduced 0.47%	1,054,400 $1.26 Million
Q2 2022 Aug 15, 2022	BUY	$1.22 - $2.25 $66,156 - $122,010	54,227 Added 5.39%	1,059,383 $1.78 Million
Q1 2022 May 16, 2022	BUY	$1.86 - $3.61 $238,678 - $463,242	128,322 Added 14.63%	1,005,156 $18.3 Million
Q4 2021 Feb 14, 2022	SELL	$3.19 - $4.89 $370,569 - $568,051	-116,166 Reduced 11.7%	876,834 $3.01 Million
Q3 2021 Nov 15, 2021	BUY	$4.14 - $22.9 $3.47 Million - $19.2 Million	838,263 Added 541.73%	993,000 $4.77 Million
Q2 2021 Aug 16, 2021	SELL	$3.84 - $6.0 $173,809 - $271,578	-45,263 Reduced 22.63%	154,737 $704,000
Q1 2021 May 17, 2021	BUY	$4.39 - $6.53 $877,999 - $1.31 Million	200,000 New	200,000 $942,000

Ticker VRPX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 11,714,600
Market Cap $7.97M
Description
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical no...

Get notified when there are updates to the investment portfolio of Sabby Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sabby Management, LLC with notifications on news.